Rockwell Medical (RMTI) Q3 2024 earnings summary

Executive summary

• Achieved profitability on a cash flow and Adjusted EBITDA basis for the second consecutive quarter in Q3 2024, with record-high quarterly product sales, gross profit, and gross margin, driven by strong sales, operational improvements, and a special large order from the largest customer.

• Net sales for Q3 2024 reached $28.3 million, up 19% year-over-year (31% excluding deferred revenue), with gross profit rising to $6.2 million and gross margin improving to 22% from 9% in Q3 2023.

• Net income for Q3 2024 was $1.7 million, compared to a net loss of $1.9 million in Q3 2023.

• Entered a multi-million dollar international distribution agreement with Nipro Medical and expanded at-home dialysis product offerings, including new supply agreements with key partners.

• Extended and expanded major customer and supply agreements, including with DaVita and AVA/aQua Dialysis, with higher pricing but expected volume declines in 2025.

Financial highlights

• Q3 2024 net sales were $28.3 million, up 19% year-over-year; nine-month sales reached $76.8 million, up 25% year-over-year.

• Gross profit for Q3 2024 was $6.2 million, a 183% increase year-over-year; nine-month gross profit was $13.9 million, up 137% year-over-year.

• Gross margin for Q3 2024 was 22%, up from 9% in Q3 2023; for the nine months ended September 30, 2024, gross margin was 18%.

• Q3 2024 net income was $1.7 million; nine-month net income was $0.3 million, a $7.2 million improvement year-over-year.

• Adjusted EBITDA for Q3 2024 was $2.8 million, compared to negative $1.2 million in Q3 2023; nine-month Adjusted EBITDA was $3.8 million, up from negative $4.4 million in 2023.

Outlook and guidance

• 2024 guidance raised: net sales $98–101 million, gross profit $15–17 million, gross margin 16–18%, Adjusted EBITDA $4–5 million.

• Q4 2024 revenue projected between $23 million and $25 million, with gross margin in line with previous quarters and continued profitability on an Adjusted EBITDA basis.

• 2025 expected to see a shift in customer mix, with a decline in sales to the largest customer (projected decrease to $31–$38 million), but a focus on higher-margin opportunities and continued Adjusted EBITDA profitability.

• Management believes current working capital is sufficient for at least the next twelve months; may raise additional capital via $4.5 million remaining under its ATM facility or other financing.